Added Value of Amyloid PET Quantification with the Centiloid Scale in Clinical Practice
Given the emergence of antiamyloid monoclonal therapies for early-stage Alzheimer disease, reliable detection of amyloidosis is critical for patient care. This study suggests that visual reads of amyloid PET may be insensitive when amyloidosis is milder but are spread across multiple regions (CL ranging from 40 to 59). Quantification of amyloid PET using the CL scale may help guide treatment of patients with mild amyloidosis who are under consideration for antiamyloid disease-modifying therapeutics.
Authors
- Mehdi Djekidel
- Graham Keir (ORCID: https://orcid.org/0000-0001-7597-8378)
- Joseph Glaser (ORCID: https://orcid.org/0000-0002-1951-1711)
- Sean Clouston (ORCID: https://orcid.org/0000-0002-6124-0329)
- Josephine N. Rini (ORCID: https://orcid.org/0009-0003-1173-8035)
- David Petrover (ORCID: https://orcid.org/0000-0002-6522-4692)
- Ana Marija Franceschi (ORCID: https://orcid.org/0000-0003-2577-9738)
- Christopher Caravella (ORCID: https://orcid.org/0000-0001-7156-2658)
- Matthew Sagnelli
- Akarsh Vijayashankar
Institutions
- Lenox Hill Hospital (US)
- Piedmont Atlanta Hospital (US)
- Stony Brook School (US)
- New York University (US)
- Stony Brook University (US)
Publication Details
- Journal
- American Journal of Neuroradiology
- Published
- 2025-09-18
- DOI
- https://doi.org/10.3174/ajnr.a8850
- Citations
- 1
- Primary Topic
- Medical Imaging Techniques and Applications
- Type
- article
- Field-Weighted Citation Impact
- 1.36